Developing advanced tests for atherosclerosis drug effectiveness and safety
Atherosclerosis assay development for drug efficacy and cytotoxicity screening
This study is working on new 3D models to help researchers better understand atherosclerosis, which is a common cause of heart problems, so they can test new drugs more effectively and safely for people with cardiovascular issues.
Quick facts
| Grant type | Sbir 1 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Endomimetics, LLC NIH-funded |
| Lab location | 1 site (Birmingham, United States) |
| Project ID | NIH-11006406 on NIH RePORTER |
What this research studies
This research focuses on creating innovative 3D models to better understand atherosclerosis, a major cause of cardiovascular disease. By utilizing advanced nanomatrix technology and artificial intelligence, the project aims to develop more accurate in vitro assays that can replicate the complexity of human atherosclerosis. These new models will allow for high-throughput testing of drugs, assessing both their effectiveness and potential toxicity in a more realistic environment than traditional 2D cultures. This approach seeks to improve drug development processes and outcomes for patients with cardiovascular conditions.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals at risk for cardiovascular diseases, particularly those with atherosclerosis or related conditions.
Not a fit: Patients with conditions unrelated to atherosclerosis or those who do not have cardiovascular risk factors may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective and safer treatments for patients suffering from atherosclerosis and related cardiovascular diseases.
How similar studies have performed: Other research has shown promise in using advanced 3D models for drug testing, indicating that this approach could lead to significant advancements in the field.
Where this research is happening
Birmingham, United States
- Endomimetics, LLC — Birmingham, United States (Active)
Researchers
- Principal investigator: Chen, Jun — Endomimetics, LLC
- Study coordinator: Chen, Jun
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.